PMID- 22197270
OWN - NLM
STAT- MEDLINE
DCOM- 20120604
LR  - 20221207
IS  - 1095-6867 (Electronic)
IS  - 0018-506X (Print)
IS  - 0018-506X (Linking)
VI  - 61
IP  - 2
DP  - 2012 Feb
TI  - The neuropharmacology of prolactin secretion elicited by 
      3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and 
      plasma analysis study.
PG  - 181-90
LID - 10.1016/j.yhbeh.2011.10.012 [doi]
AB  - 3,4-methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine that is 
      widely abused as the street drug "ecstasy". Racemic MDMA (S,R(+/-)-MDMA) and its 
      stereoisomers elicit complex spectrums of psychobiological, neurochemical, and 
      hormonal effects. In this regard, recent findings demonstrated that S,R(+/-)-MDMA 
      and its stereoisomer R(-)-MDMA elicit increases in striatal extracellular 
      serotonin levels and plasma levels of the hormone prolactin in rhesus monkeys. In 
      the present mechanistic study, we evaluated the role of the serotonin transporter 
      and the 5-HT(2A) receptor in S,R(+/-)-MDMA- and R(-)-MDMA-elicited prolactin 
      secretion in rhesus monkeys through concurrent microdialysis and plasma analysis 
      determinations and drug interaction experiments. Concurrent neurochemical and 
      hormone determinations showed a strong positive temporal correlation between 
      serotonin release and prolactin secretion. Consistent with their distinct 
      mechanisms of action and previous studies showing that the serotonin transporter 
      inhibitor fluoxetine attenuates the behavioral and neurochemical effects of 
      S,R(+/-)-MDMA, pretreatment with fluoxetine attenuated serotonin release elicited 
      by either S,R(+/-)-MDMA or R(-)-MDMA. As hypothesized, at a dose that had no 
      significant effects on circulating prolactin levels when administered alone, 
      fluoxetine also attenuated prolactin secretion elicited by S,R(+/-)-MDMA. In 
      contrast, combined pretreatment with both fluoxetine and the selective 5-HT(2A) 
      receptor antagonist M100907 was required to attenuate prolactin secretion 
      elicited by R(-)-MDMA, suggesting that this stereoisomer of S,R(+/-)-MDMA elicits 
      prolactin secretion through both serotonin release and direct agonism of 5-HT(2A) 
      receptors. Accordingly, these findings inform our understanding of the 
      neuropharmacology of both S,R(+/-)-MDMA and R(-)-MDMA and the regulation of 
      prolactin secretion.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Murnane, K S
AU  - Murnane KS
AD  - Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate 
      Research Center, Atlanta, GA 30322, USA.
FAU - Kimmel, H L
AU  - Kimmel HL
FAU - Rice, K C
AU  - Rice KC
FAU - Howell, L L
AU  - Howell LL
LA  - eng
GR  - K02 DA000517/DA/NIDA NIH HHS/United States
GR  - Z01 DA000517/Intramural NIH HHS/United States
GR  - P51 RR000165/RR/NCRR NIH HHS/United States
GR  - DA010344/DA/NIDA NIH HHS/United States
GR  - K05 DA031246/DA/NIDA NIH HHS/United States
GR  - K02 DA000517-10/DA/NIDA NIH HHS/United States
GR  - DA000517/DA/NIDA NIH HHS/United States
GR  - R37 DA010344-16/DA/NIDA NIH HHS/United States
GR  - RR00165/RR/NCRR NIH HHS/United States
GR  - R37 DA010344/DA/NIDA NIH HHS/United States
GR  - R01 DA010344/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20111214
PL  - United States
TA  - Horm Behav
JT  - Hormones and behavior
JID - 0217764
RN  - 0 (Fluorobenzenes)
RN  - 0 (Hallucinogens)
RN  - 0 (Piperidines)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 9002-62-4 (Prolactin)
RN  - EW71EE171J (volinanserin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Female
MH  - Fluorobenzenes/pharmacology
MH  - Fluoxetine/pharmacology
MH  - Hallucinogens/blood/*pharmacology
MH  - Macaca mulatta
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*blood/*pharmacology
MH  - Piperidines/pharmacology
MH  - Prolactin/*blood/*metabolism
MH  - Serotonin Agents/blood/*pharmacology
MH  - Serotonin Antagonists/pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/pharmacokinetics
MH  - Stereoisomerism
MH  - Time Factors
PMC - PMC3278534
MID - NIHMS349769
COIS- Disclosure / Conflict of interest: None of the authors of this manuscript have 
      any conflicts of interest related to its content.
EDAT- 2011/12/27 06:00
MHDA- 2012/06/05 06:00
PMCR- 2013/02/01
CRDT- 2011/12/27 06:00
PHST- 2011/05/11 00:00 [received]
PHST- 2011/10/21 00:00 [revised]
PHST- 2011/10/25 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/06/05 06:00 [medline]
PHST- 2013/02/01 00:00 [pmc-release]
AID - S0018-506X(11)00278-9 [pii]
AID - 10.1016/j.yhbeh.2011.10.012 [doi]
PST - ppublish
SO  - Horm Behav. 2012 Feb;61(2):181-90. doi: 10.1016/j.yhbeh.2011.10.012. Epub 2011 
      Dec 14.